Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Goreisan, a traditional Chinese medicine, is used in Japan for edema, nephrotic syndrome, uremia, and diabetes mellitus. Animal experimental studies have suggested its potential to reduce proteinuria and preserve kidney function. However, there has been no clinical study investigating the effects of Goreisan on chronic kidney disease (CKD) to date. Therefore, the present study aimed to examine the clinical impact of Goreisan on the amount of proteinuria and estimated glomerular filtration rate (eGFR) in patients with CKD.
This retrospective observational study included patients with CKD who attended our outpatient clinic as of November 30, 2022, and had taken Goreisan for at least two months between March 2008 and November 2022. The inclusion criteria were individuals aged 20 years or older. The exclusion criteria included those with an eGFR <15mL/min/1.73m2 and those with adjusted doses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or sodium-glucose cotransporter-2 inhibitors in the two months preceding and following the initiation of Goreisan. The study focused on assessing changes in eGFR, the amount of proteinuria, and systolic blood pressure at baseline and 2 months after the initiation of Goreisan.
Ten patients were enrolled in this study. The amount of proteinuria exhibited a significant reduction two months after initiating Goreisan compared to the baseline (1.51 [1.04-2.81] versus 1.26 [0.55-1.35] g/gCr, P<0.05). However, no significant alteration in eGFR was observed before and after the initiation of Goreisan (27.6 [18.7-48.6] versus 29.6 [20.2-47.6] mL/min/1.73 m², P=0.30). Additionally, there was no noteworthy change in systolic blood pressure before and after initiating Goreisan (122±17 versus 119±12 mmHg, P=0.30).
The findings from our study indicated that Goreisan reduces the amount of proteinuria in patients with CKD, regardless of blood pressure changes. Our results imply that Goreisan could be one of the potential medications for patients with CKD.
